NewLimit, the aging-biotech backed by investors including Founders Fund, Thrive Capital, and Lilly Ventures, raised $435 million in a Series C to fund its first-in-human cell age reprogramming program. The round follows faster-than-expected scientific progress: after previously signaling it would take several years to reach a clinical candidate, NewLimit says its lead liver-targeting construct emerged from its transcription-factor screening pipeline by the end of last year. The company packages transcription-factor combinations into lipid nanoparticles in mRNA form for delivery to target tissues. In preclinical work, it reported improved regenerative capacity in old livers and increased resilience in alcohol-related stress models. NewLimit plans to begin Phase 1 testing next year, with initial enrollment focused on patients with fatty liver disease. The company expects the trial to be the first human readout of liver age reprogramming and to expand its portfolio based on early results.